Cargando…
Suvorexant: a promising, novel treatment for insomnia
Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of v...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772996/ https://www.ncbi.nlm.nih.gov/pubmed/26955275 http://dx.doi.org/10.2147/NDT.S31495 |
_version_ | 1782418651650981888 |
---|---|
author | Lee-Iannotti, Joyce K Parish, James M |
author_facet | Lee-Iannotti, Joyce K Parish, James M |
author_sort | Lee-Iannotti, Joyce K |
collection | PubMed |
description | Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others. |
format | Online Article Text |
id | pubmed-4772996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-47729962016-03-07 Suvorexant: a promising, novel treatment for insomnia Lee-Iannotti, Joyce K Parish, James M Neuropsychiatr Dis Treat Review Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others. Dove Medical Press 2016-02-25 /pmc/articles/PMC4772996/ /pubmed/26955275 http://dx.doi.org/10.2147/NDT.S31495 Text en © 2016 Lee-Iannotti and Parish. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Lee-Iannotti, Joyce K Parish, James M Suvorexant: a promising, novel treatment for insomnia |
title | Suvorexant: a promising, novel treatment for insomnia |
title_full | Suvorexant: a promising, novel treatment for insomnia |
title_fullStr | Suvorexant: a promising, novel treatment for insomnia |
title_full_unstemmed | Suvorexant: a promising, novel treatment for insomnia |
title_short | Suvorexant: a promising, novel treatment for insomnia |
title_sort | suvorexant: a promising, novel treatment for insomnia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772996/ https://www.ncbi.nlm.nih.gov/pubmed/26955275 http://dx.doi.org/10.2147/NDT.S31495 |
work_keys_str_mv | AT leeiannottijoycek suvorexantapromisingnoveltreatmentforinsomnia AT parishjamesm suvorexantapromisingnoveltreatmentforinsomnia |